HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Witzens-Harig, M. Articles by Ho, A. D. Search for Related Content PubMed PubMed Citation Articles by Witzens-Harig, M. Articles by Ho, A. D.

TRANSLATIONAL AND CLINICAL RESEARCH

Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34⁺-Selected Peripheral Blood Progenitor Cells

^aDepartment of Hematology and Oncology, University Hospital Heidelberg and
^bCentral Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany

Key Words. CD34⁺-selected PBPC • Long-term follow-up • Graft engineering • Lymphoma • High-dose chemotherapy

Correspondence: Mathias Witzens-Harig, M.D., University of Heidelberg Hospital—Internal Medicine V, INF 410 Heidelberg 69120 Germany. Telephone: +49-6221-5631341; Fax: +49-6221-565721; e-mail: mathias.witzens-harig{at}med.uni-heidelberg.de

Received December 7, 2005; accepted for publication September 8, 2006.


Graft engineering by CD34⁺ selection of peripheral blood progenitor cells (PBPC) has been used in non-Hodgkin lymphoma (NHL) with the aim to reduce relapse related to tumor cells within the graft. From September 1995 to January 2000, 39 patients with newly diagnosed (n = 31) or relapsed (n = 8) NHL were treated in our institution with myeloablative therapy followed by CD34⁺ selected autologous PBPC transplantation. Thirty-one patients were diagnosed with follicular lymphoma, and eight patients with mantle-cell lymphoma. All patients had advanced disease (26% of patients stage III and 74% stage IV, Ann Arbor classification). Induction therapy resulted in a complete remission in 17 patients and a partial remission in 22 patients. PBPC were mobilized after cytotoxic chemotherapy with granulocyte colony-stimulating factor support. CD34⁺ selection was performed using immunomagnetic beads (Baxter Isolex 300SA or 300i Magnetic Cell Separation System). Most patients (85%) received total body irradiation and high-dose cyclophosphamide as myeloablative regimen. Twelve patients also received rituximab 375 mg/m² before radiation and before the start of the cyclophosphamide treatment. The mean CD34⁺ cell number for transplantation was 6.5 x 10⁶ CD34⁺ cells/kg of body weight. Platelet recovery (>20,000/µl median on day 13) and leukocyte recovery (>1,000/µl median on day 12) were within expected range. The estimated median follow-up was 47 months. The probabilities of freedom from progression, overall survival, and event-free survival 4 years after transplantation were 96%, 90%, and 87%, respectively, for patients with follicular lymphoma and 42%, 63%, and 33%, respectively, for patients with mantle-cell lymphoma. Risk factors for relapse were age and extranodal manifestation of disease. The rate of lethal infections in the 12-month follow-up period was 8%. We conclude that CD34⁺ selection of autologous transplants following myeloablative therapy is feasible and results in long-term remission in the majority of patients, but the procedure is probably related to a higher rate of lethal infections.